Interim safety analysis of a compassionate-use program (CUP) and early-access program (EAP) providing cabazitaxel (Cbz) plus prednisone (P) to patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) previously treated with docetaxel


Malik Z. I. , Di Lorenzo G., Basaran M. , Ardavanis A., Parente P., de Schultz W., ...More

49th Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), Illinois, United States Of America, 31 May - 04 June 2013, vol.31 identifier

  • Publication Type: Conference Paper / Summary Text
  • Volume: 31
  • City: Illinois
  • Country: United States Of America